Bio
B Losada Vila is affiliated with Complutense Madrid, Spain. She has contributed research papers in the fields of Head and Neck Cancer, Brain Metastases and Treatment, Lung Cancer Diagnosis and Treatment, Pulmonary and Respiratory Medicine, and Reproductive Medicine. Her works have been published in reputable journals such as the Global Journal of Medical Research.
Experience
Universidad Complutense de Madrid
0 - 0Editors Role
Reviewer
GJMR
2017 - PresentResearch
Chemoradiotherapy or Induction Chemotherapy Followed by Chemoradiotherapy. University Hospital Fuenlabrada: Our Experience in 10 years.
Head and neck tumors are diagnosed in locally advanced stages up to 60%. The controversy lies in the choice between chemoradiotherapy vs induction chemotherapy. Retrospective descriptive study with 53 patients undergoing induction chemotherapy alone vs CRT + CRT in which we analyze the tolerability, organ preservation, recurrence rates, overall survival (OS) and disease-free survival (DFS). Within the group of induction (A), 86% (24/28) received 3 cycles TPF, while 14% (4/28) were treated with a doublet (platinum + taxol), being able to meet the treatment without delay or dose reduction of only 50%. Within non-induction group (B), 80% receive all doses and without delay, while 20% (5/25) failed to finish, fell 80 % (4/5) of them. They are not comparable groups as the most important difference is that those with more advanced (N2 disease) are in group A (92.8% cT3-T4 or N2) versus Group B (32% cT3N0). Conclusions: _ The Profile of our patients in the group of non-induction have more comorbidities and the earliest stages. Recurrence rates are similar in both groups, with a higher relapse and metastatic disease in the induction group (group A) because of more advanced tumors. _ We have to study new strategies for improving tolerance induction chemotherapy with cetuximab or nab-paclitaxel, and selecting best ones should receive concomitant cetuximab + RT.
Rectal Adenocarcinoma with Synchronous Brain Metastasis and Prolonged Overall Survival (OS)
A 61 years old woman with dizziness and gait disturbance in relation to brain metastases of a rectal adenocarcinoma (cT3N1M1). CT showed an unique frontal lesion and no further disease in other organs. Performance Status 1, so Digestive Tumors Committee decides surgical treatment of frontal brain metastasis and the histologic postsurgical examination showed microscopic affected margins. Then, radiation therapy (RT) of brain with radiosurgery and short course 5x5 of the primary tumor with low anterior resection was completed. After 2 months of brain RT, liver progression was discovered and then we decided neoadjuvant chemotherapy mFOLFOX6 and bevacizumab x 5 cycles with stable liver metastases and no other lesions. Following, limited liver resection and adjuvant chemotherapy was performed with the same schedule. No signs of tumor recurrence and more than 13 and 24 months of disease-free survival (DFS) and overall survival (OS) respectively was achieved in a metastasic cancer (brain metastasis) with usually OS 3 months.
